---
title: 'Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar
  Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up
  Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of
  a Real-World Propensity-Matched Multi-Centre Australian Cohort Study'
date: '2024-09-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39272868/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240914193229&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Percutaneous ablation is recommended in Barcelona Clinic Liver Cancer
  (BCLC) stage 0/A patients with HCC ≤3 cm as a curative treatment modality alongside
  surgical resection and liver transplantation. However, trans-arterial chemo-embolisation
  (TACE) is commonly used in the real-world as an initial treatment in patients with
  single small HCC in contrast to widely accepted clinical practice guidelines which
  typically describe TACE as a treatment for intermediate-stage HCC. We performed
  ...
disable_comments: true
---
Percutaneous ablation is recommended in Barcelona Clinic Liver Cancer (BCLC) stage 0/A patients with HCC ≤3 cm as a curative treatment modality alongside surgical resection and liver transplantation. However, trans-arterial chemo-embolisation (TACE) is commonly used in the real-world as an initial treatment in patients with single small HCC in contrast to widely accepted clinical practice guidelines which typically describe TACE as a treatment for intermediate-stage HCC. We performed ...